Significant Ownership of Bellevue Group AG

Signature - Title
/s/ Stefano Montalbano - Stefano Montalbano/ Chief Financial Officer
Location
Zurich
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by Bellevue Group AG.

Notify me when Bellevue Group AG files a new Schedule 13D/G report.

⭐ Subscribe ⭐

Significant Ownership of Bellevue Group AG

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
IMCR Immunocore Holdings plc Ordinary shares 5.6% $101,607,853 2,796,803 Bellevue Group AG 20 Aug 2025
CLDX Celldex Therapeutics, Inc. Common Stock 5.4% $93,589,097 3,617,669 Bellevue Group AG 18 Aug 2025
AGIO Agios Pharmaceuticals, Inc. Common Stock 0% $0 -$142,398,726 0 -100% Bellevue Group AG 19 Nov 2025
MGNX MacroGenics, Inc. Common Stock 0% $0 -$13,901,948 0 -100% Bellevue Group AG 05 Dec 2025

Schedules 13D/G Reported by Bellevue Group AG:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Filing Date
* An asterisk sign (*) next to the price indicates that the price is likely invalid.